Navigation Links
Vinorelbine in Medical News

Mayo Clinic Researchers Say Triple Drug Combination is Promising Option to Treat Metastatic HER2+ Breast Cancer

...b -- always causes hair loss, Dr. Tan says. All of the agents are approved for use by the U.S. Food and Drug Administration for cancer, although vinorelbine has not been approved for this particular treatment regimen in the U.S., the researchers say. Capecitabine chemotherapy is not usually paired wit...

Triple drug combination is promising option to treat metastatic HER2+ breast cancer

...uzumab always causes hair loss, Dr. Tan says. All of the agents are approved for use by the U.S. Food and Drug Administration for cancer, although vinorelbine has not been approved for this particular treatment regimen in the U.S., the researchers say. Capecitabine chemotherapy is not usually paired with t...

Twenty New Abstracts on Oral Xeloda(R) (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium

...treated with oral Xeloda monotherapy compared with vinorelbine monotherapy in one study or gemcitabine monotherap...total health care costs than patients treated with vinorelbine monotherapy or gemcitabine monotherapy. Th...py-related expenditures than those associated with vinorelbine in women with metastatic breast cancer (Lead Autho...

Chemo for Mesothelioma Offers Limited Survival Benefits

... mitomycin, vinblastine and cisplatin every three weeks or one injection of vinorelbine every week for 12 weeks) in addition to active symptom control (ACS) treatm...l survival or quality of life. However, exploratory analyses suggested that vinorelbine merits further investigation," the authors concluded. More information ...

Other highlights in the April 8 JNCI

... failed to respond to the initial two cycles of TAC were randomly assigned to either four additional cycles of TAC or four cycles of capecitabine plus vinorelbine (NX). Increasing the number of TAC cycles or switching regimens did not appear to improve outcomes. Only 5.3 percent of women on TAC achieved a comple...

Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.'s Drug Pipeline

...D., presented the phase III results of XYOTAX in first-line treatment of non-small cell lung cancer noting that "equivalent survival to gemcitabine or vinorelbine in poor performance status patients and the reduction in toxicity coupled with the convenience of administration is very important and it's on the bas...

Gene Screening Points Way to More Effective Chemotherapy

...The researchers then re-tested the six genes that showed the most dramatic effect with paclitaxel and tried the same test using the chemotherapy drugs vinorelbine (Navelbine) and gemcitabine (Gemzar), but the results were not as dramatic as those seen for paclitaxel. “Our studies using additional drugs indicate ...

Trails to detect effective breast cancer drugs that reduces recurrences

...started to determine and help patients to have a recurrence free survival after breast cancer surgery. The chemotherapy drugs docetaxel (Taxotere) and vinorelbine (Navelbine) are tested to analyze the outcomes.// It was previously reported by the Finnish researchers that patients who received infusions of tr...

Treatment of Breast Cancer with Herceptin for Nine Weeks

...searchers to analyze the safety and efficiency of Herceptin in 1010 women who had breast cancer. The women included in the study received docetaxel or vinorelbine and then FEC (5-fluorouracil, epirubicin, cyclophosphamide).Those whose HER-2 protein were increased Herceptin was given for nine weeks or no Hercepti...

Enhancing Survival Rate Of Lung Cancer Patients

...ycles of cisplatin-based chemotherapy or observation. In addition to cisplatin, the drug etoposide was given to about 56 percent of patients; the drug vinorelbine was given to about 26 percent of patients; vinblastine was given to 11 percent of patients, and vindesine was given to nearly 6 percent of patients. O...
Vinorelbine in Medical Technology

Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology

Results are basis for CTI's Marketing Authorization Application currently under review by the EMEA SEATTLE, July 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC ; MTA) today announced the publication of results from its randomized phase III trial ...

XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer

ASCO publication highlights health care cost benefit of bioengineering paclitaxel CHICAGO, June 05, 2007 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) announced that data published in the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO) abstracts showed reduced med...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

...d at SABCS include: RAD001 Multicenter Phase I clinical trial of daily and weekly RAD001 (everolimus) in combination with vinorelbine and trastuzumab in HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab ( SABCS Abstract #406: Friday, December 12, 200...

Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments

... clinical trial of daily and weekly RAD001 (everolimus) in combination with vinorelbine and trastuzumab in patients with HER2-overexpressing metastatic breast canc...RAD001 (20 mg, 30 mg, 50 mg and 70 mg) regimens. Patients were administered vinorelbine (25 mg/m2, IV over 10-15 min on days 1 and 8 q3w) and trastuzumab (4 mg/kg ...

ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study

...fusion site reactions with emulsion formulation of vinorelbine (ANX-530) compared to vinorelbine solution," will be published in the 2008 Proceedin...and pleased that our goal to improve the safety of vinorelbine has been observed in the clinic," stated Evan M. L...

European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review

...rial, single-agent XYOTAX resulted in comparable survival to gemcitabine or vinorelbine in first-line patients and, with the exception of neuropathy known to be as...2 patients with NSCLC. STELLAR 4 tested XYOTAX versus either gemcitabine or vinorelbine for the potential first-line treatment of PS2 patients with NSCLC. While th...

Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)

...rial, single-agent XYOTAX resulted in comparable survival to gemcitabine or vinorelbine in first-line patients and, with the exception of neuropathy known to be as...2 patients with NSCLC. STELLAR 4 tested XYOTAX versus either gemcitabine or vinorelbine for the potential first-line treatment of PS2 patients with NSCLC. About ...

ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study

...n. Worldwide annual sales of Navelbine and generic vinorelbine in 2006 were approximately $200 million. The bioe...lsion) ANX-530 is a novel emulsion formulation of vinorelbine tartrate, a generic chemotherapy agent. ANX-530 is...from intravenous-delivery of vinorelbine tartrate. vinorelbine tartrate works by disrupting microtubule formation...

ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study

...vel, emulsion formulation of vinorelbine tartrate. vinorelbine tartrate, marketed under the brand name Navelbine(...n. Worldwide annual sales of Navelbine and generic vinorelbine in 2006 were approximately $200 million. "Complet...lsion) ANX-530 is a novel emulsion formulation of vinorelbine tartrate, a generic chemotherapy agent. ANX-530 is...

Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy

..., the median time to first disease progression in the patients treated with vinorelbine was only 4.4 months. Values for "prostate-specific antigen" (PSA), an est...ve, Open Label, Randomized Phase II Trial of Weekly Docetaxel Versus Weekly vinorelbine as First Line Chemotherapy in Patients with Androgen Independent Prostate C...
Vinorelbine in Biological Technology

ADVENTRX Provides Update on Strategic Transaction Process

... About ANX-530 (vinorelbine emulsion) ANX-530 is a novel emulsion formulation of the chemotherapy drug vinorelbine. ANX-530 emulsifies vinorelbine into a homogeneous suspension of nanoparticles that is designed to protect the venous endothelium during administration into a peripheral vein. Navel...

ADVENTRX Announces Further Cost-Cutting Measures

...2010. About ANX-530 (vinorelbine emulsion) ANX-530 is a novel emulsion formulation of the chemotherapy drug vinorelbine. ANX-530 emulsifies vinorelbine into a homogeneous suspension of nanoparticles that is designed to protect the venous endothelium during administration into a peripheral vein. Navel...

ADVENTRX Announces Restructuring and Cost Reduction Initiatives

...e same link. About ANX-530 (vinorelbine emulsion) ANX-530 is a novel emulsion formulation of the chemotherapy drug vinorelbine. ANX-530 emulsifies vinorelbine into a homogeneous suspension of nanoparticles that is designed to protect the venous endothelium during administration into a peripheral vein. Navelb...

ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study

...lence observed between an emulsion formulation of vinorelbine (ANX-530) and vinorelbine solution in a clinical study of patients with advanced cancer," was present...tic breast cancer. Worldwide sales of Navelbine and generic formulations of vinorelbine in 2006 were in excess of $200 million. Navelbine and its generic equival...

ADVENTRX Creates Executive Vice President Position and Announces New Chief Financial Officer

...ime to be joining the ADVENTRX management team," stated Mr. Bagnall. "The company has made tremendous progress with its novel emulsion formulations of vinorelbine and docetaxel. I look forward to the continued development and anticipated commercialization of these product candidates, as well as the continued dev...

Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology

...fusion site reactions with emulsion formulation of vinorelbine (ANX-530) compared to vinorelbine solution," will ...ide sales of Navelbine and generic formulations of vinorelbine in 2006 were in excess of $200 million. Navelbin...jection site reactions. Our formulation emulsifies vinorelbine into a homogeneous suspension of nanoparticles tha...

ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting

...alence observed between an emulsion formulation of vinorelbine (ANX-530) and vinorelbine solution in a clinical s...ection site reactions from intravenous delivery of vinorelbine tartrate. Vinorelbine tartrate works by disrupting...the vinca alkaloid class of antineoplastic agents. vinorelbine is indicated as a single agent or in combination w...

Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule

... within six weeks. Most physicians will utilize single-agent gemcitabine or vinorelbine to treat these frail patients. Current treatments also have limited effecti...ELLAR 4 phase III clinical trial tested XYOTAX versus either gemcitabine or vinorelbine for the potential first-line treatment of poor performance status (PS2) pat...

ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results

...atment of metastatic colorectal cancer," stated Evan M. Levine, chief executive officer of ADVENTRX. "We are encouraged by continued progress with our vinorelbine emulsion product candidate ANX-530 and our docetaxel emulsion product candidate ANX-514. We expect that our emulsion product candidates will require l...

ADVENTRX Appoints Vice President of Commercialization

...lsion) ANX-530 is a novel emulsion formulation of vinorelbine tartrate, a generic chemotherapy agent. ANX-530 is...nd severity of vein irritation from IV-delivery of vinorelbine tartrate. Vinorelbine tartrate works by disrupting...the vinca alkaloid class of antineoplastic agents. vinorelbine is indicated as a single agent or in combination w...
Other Tags
(Date:1/22/2015)... The federal court overseeing thousands of vaginal mesh ... District of West Virginia has upheld a $2 million verdict ... trial. In an Order dated January 21st, the Court denied ... C.R. Bard had not proven a miscarriage of justice. (Cisson ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Autocarinsurancebest.com has released ... purchasing a commercial auto insurance policy . , Auto ... their vehicles. It is no longer necessary to call an ... are now available online on a single website: http://autocarinsurancebest.com/ ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
(Date:1/22/2015)... Four years since the release of their debut ... the marriage of Avasa & Matthew Love – the duo are ... for release through White Swan Records on February 24, 2015. , ... sacred path available to all of us to walk out of ...
(Date:1/22/2015)... a famous dress online store for wedding dresses and other ... of wedding dresses , and launches a site-wide women’s dress ... on your big day; the wedding gown is the most ... find the most suitable wedding dress. Now, we are proud ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
(Date:1/22/2015)... ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform its shareholders ... Washington,s Department of Licensing, in the United States, awarded ... for driver,s licenses and identification cards to its subsidiary, Valid ... start in January 2015, with enrollment and card production starting ...
(Date:1/22/2015)...  A man-made form of insulin delivered by nasal spray ... adults with mild cognitive impairment and Alzheimer,s disease dementia, ... Wake Forest Baptist Medical Center. The study,s ... impairment (MCI) or mild to moderate Alzheimer,s dementia (AD). ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... addition of the "Global Wearable Technologies Market ... Share, Overview, Trends and Forecast 2014-2020" report ... Technologies are smart devices that can be worn ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
Other Contents